Advertisement

Topics

Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018

07:00 EST 15 Feb 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
OpRegen® is in a Phase I/IIa clinical trial for dry-AMD Vision Restoration – Our 3-Dimensional Retinal Tissue Program BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology ...

Other Sources for this Article

Investor Contact:
BioTime
David Nakasone, 510-871-4188
Dnakasone@biotime.com
or
Media Contact:
JQA Partners, Inc.
Jules Abraham, 917-885-7378
jabraham@jqapartners.com

NEXT ARTICLE

More From BioPortfolio on "Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...